Compile Data Set for Download or QSAR
Report error Found 218 Enz. Inhib. hit(s) with all data for entry = 1313
TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614685(US20230271931, Example 43 | 2-(1-Cyclobutyl- 1H-py...)
Affinity DataIC50: 2.80nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614791(US20230271931, Example 149 | 2-(2-Cyclobutyl- 1,3-...)
Affinity DataIC50: 3.20nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614804(US20230271931, Example 168 | 2-(2-Cyclobutyl- 1,3-...)
Affinity DataIC50: 3.30nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614790(US20230271931, Example 148 | 2-(2-Cyclobutyl- 1,3-...)
Affinity DataIC50: 3.40nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614803(US20230271931, Example 167 | 2-(2-Cyclopentyl- 1,3...)
Affinity DataIC50: 3.40nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614743(US20230271931, Example 101 | 3-Chloro-2-(1- cyclob...)
Affinity DataIC50: 3.5nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614683(US20230271931, Example 41 | 5-({[1-(4- Chloro-2- f...)
Affinity DataIC50: 3.70nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614788(US20230271931, Example 146 | 5-({[1-(4-Chloro- 2- ...)
Affinity DataIC50: 3.70nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614684(US20230271931, Example 42 | 2-(1-Cyclobutyl- 1H-py...)
Affinity DataIC50: 4.10nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614743(US20230271931, Example 101 | 3-Chloro-2-(1- cyclob...)
Affinity DataIC50: 5.5nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614679(US20230271931, Example 37 | 2-(1-Cyclobutyl- 1H-py...)
Affinity DataIC50: 5.60nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614667(US20230271931, Example 25 | 2-(1-Cyclobutyl- 1H-py...)
Affinity DataIC50: 5.90nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614678(US20230271931, Example 36 | 2-(1-Cyclobutyl- 1H-py...)
Affinity DataIC50: 6nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614681(US20230271931, Example 39 | 2-(1-Cyclobutyl- 1H-py...)
Affinity DataIC50: 6.10nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614684(US20230271931, Example 42 | 2-(1-Cyclobutyl- 1H-py...)
Affinity DataIC50: 6.30nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614643(US20230271931, Example 1)
Affinity DataIC50: 6.5nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614685(US20230271931, Example 43 | 2-(1-Cyclobutyl- 1H-py...)
Affinity DataIC50: 7nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614733(US20230271931, Example 91 | 2-(4-tert-Butyl- 1H-im...)
Affinity DataIC50: 7.60nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614644(US20230271931, Example 2 | US20230271931, Example ...)
Affinity DataIC50: 8.10nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614794(US20230271931, Example 152 | 5-[({1-[2-Fluoro- 4- ...)
Affinity DataIC50: 8.10nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614748(US20230271931, Example 106 | 3-Chloro-2-[6- (1,1- ...)
Affinity DataIC50: 8.40nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614795(US20230271931, Example 153 | 2-[1-(1- Cyclopropyle...)
Affinity DataIC50: 8.70nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614683(US20230271931, Example 41 | 5-({[1-(4- Chloro-2- f...)
Affinity DataIC50: 8.80nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614742(US20230271931, Example 100 | 3-Chloro-2-(1- cyclob...)
Affinity DataIC50: 8.90nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614730(US20230271931, Example 88 | 3-Fluoro-5-[({1- [2-fl...)
Affinity DataIC50: 10nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614739(US20230271931, Example 97 | 2-[6-(1,1- Difluoropro...)
Affinity DataIC50: 10nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614682(US20230271931, Example 40 | 2-(1-Cyclobutyl- 1H-py...)
Affinity DataIC50: 11nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614717(US20230271931, Example 75 | 5-[({1-[2-Fluoro- 4- (...)
Affinity DataIC50: 11nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614718(US20230271931, Example 76 | 2-[1-(2,2- Dimethylpro...)
Affinity DataIC50: 11nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614769(US20230271931, Example 127 | 2-[1- (Cyclopropyl- m...)
Affinity DataIC50: 11nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614645(US20230271931, Example 3)
Affinity DataIC50: 12nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614671(US20230271931, Example 29 | 3-Fluoro-5-[({1- [2-fl...)
Affinity DataIC50: 13nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614719(US20230271931, Example 77 | 2-[1-(2,2- Dimethylpro...)
Affinity DataIC50: 13nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614737(US20230271931, Example 95 | 2-[6- (Difluoromethyl)...)
Affinity DataIC50: 13nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614742(US20230271931, Example 100 | 3-Chloro-2-(1- cyclob...)
Affinity DataIC50: 13nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614750(US20230271931, Example 108 | 2-(1-Cyclobutyl- 1H-p...)
Affinity DataIC50: 13nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614764(US20230271931, Example 122 | 2-(1-Cyclohexyl- 1H-p...)
Affinity DataIC50: 13nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614781(US20230271931, Example 139 | 2-(1-Ethyl-1H- pyrazo...)
Affinity DataIC50: 13nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614789(US20230271931, Example 147 | 2-(2-Cyclobutyl- 1,3-...)
Affinity DataIC50: 13nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614667(US20230271931, Example 25 | 2-(1-Cyclobutyl- 1H-py...)
Affinity DataIC50: 14nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614678(US20230271931, Example 36 | 2-(1-Cyclobutyl- 1H-py...)
Affinity DataIC50: 14nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614731(US20230271931, Example 89 | 3-Fluoro-5-[({1- [2-fl...)
Affinity DataIC50: 14nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614750(US20230271931, Example 108 | 2-(1-Cyclobutyl- 1H-p...)
Affinity DataIC50: 14nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614768(US20230271931, Example 126 | 2-[1- (Cyclopropylmet...)
Affinity DataIC50: 14nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614799(US20230271931, Example 162 | 2-(6-Ethylpyridin- 3-...)
Affinity DataIC50: 14nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614695(US20230271931, Example 53 | 5-({[1-(4- Chloro-2- f...)
Affinity DataIC50: 15nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614716(US20230271931, Example 74 | 5-[({1-[2-Fluoro- 4- (...)
Affinity DataIC50: 15nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614798(US20230271931, Example 161 | 2-(6-Ethylpyridin- 3-...)
Affinity DataIC50: 15nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614682(US20230271931, Example 40 | 2-(1-Cyclobutyl- 1H-py...)
Affinity DataIC50: 16nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

TargetB1 bradykinin receptor(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM614693(US20230271931, Example 51 | 2-(1-Cyclobutyl- 1H-py...)
Affinity DataIC50: 17nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 218 total ) | Next | Last >>
Jump to: